Tonix Pharmaceuticals (TNXP) Stock: Gains On Coming Poster Presentations

0

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) is having a pretty strong start to the trading session this morning, and for good reason. The company announced that it will be providing various poster presentations with regard to clinical data surrounding Tonmya*, also known as TNX-102 SL. Of course, this caused excitement among investors, sending the stock toward the sky. As is almost always the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (9:31), TNXP is trading at $3.12 per share after a gain of $0.17 per share or 5.76% thus far today.





TNXP Gains On Clinical Update

As mentioned above, Tonix Pharmaceuticals is having a relatively strong start in today’s trading session after providing investors with news of a coming clinical update. The company said that it would be providing poster presentations at the 2017 Military Health System Research Symposium, which will be held August 27th through August 30th in Kissimmee Florida. Chief Medical Officer of TNXP, Gregory M. Sullivan, M.D., will be the presenter of the following poster presentations…




  • Poster #521: Phase 2 Trial of a Low Dose, Bedtime, Proprietary Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD: Mediators and Moderators of Treatment Response (Abstract ID: MHSRS-17-1685).
  • Poster #519: Efficacy of a Low Dose, Bedtime, Proprietary Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD: Study Protocol of a Phase 3 Randomized Placebo-Controlled Trial (P301) (Abstract ID: MHSRS-17-1626).

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on TNXP. In particular, we’re interested in following the ongoing work surrounding TNX-102 SL as the treatment has shown some promising results in previous studies. Not to mention, the breakthrough therapy designation makes it an even more promising prospect. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









LEAVE A REPLY

Please enter your comment!
Please enter your name here